心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Am Heart J：稳定性冠心病双重抗血小板治疗进展

2014-06-26 高晓方 译 医学论坛网

稳定性冠心病双重抗血小板治疗进展
关注

法国一项研究表明，在当前临床实践中相当一部分稳定性冠脉疾病患者接受双重抗血小板治疗(DAPT)。研究者表示，虽然未观察到出血风险增加，但也不支持延长DAPT时间。论文于6月23日在线发表于《美国心脏杂志》(Am Heart J)。 此项研究从一项稳定性冠脉疾病前瞻性登记中纳入3691例患者，并依据进入系统时抗血小板治疗方案将受试者分为DAPT组和单一抗血小板治疗(SAPT)组。主要转归由心血管死

法国一项研究表明，在当前临床实践中相当一部分稳定性冠脉疾病患者接受双重抗血小板治疗(DAPT)。研究者表示，虽然未观察到出血风险增加，但也不支持延长DAPT时间。论文于6月23日在线发表于《美国心脏杂志》(Am Heart J)。

此项研究从一项稳定性冠脉疾病前瞻性登记中纳入3691例患者，并依据进入系统时抗血小板治疗方案将受试者分为DAPT组和单一抗血小板治疗(SAPT)组。主要转归由心血管死亡、心肌梗死或卒中组成。

结果显示，共有868例(24%)患者接受DAPT。与DAPT应用呈正相关性的因素包括入组时持续性心绞痛、体重指数、1至3年心肌梗死、1至3年心肌血运重建、多血管冠状动脉疾病、既往药物洗脱支架置入以及既往主动脉或外周血管介入;呈负相关的因素包括年龄、既往冠脉搭桥和左室射血分数。

2年时SAPT和DAPT组患者的主要转归发生率相似(4.6%对5.5%)，出血发生率亦相似。

原始出处：

Gilles Lemesle, MDemail address, Nicolas Lamblin, MD, PhD, Thibaud Meurice, MD, Olivier Tricot, MD, Robert Lallemant, MD, Olivier Nugue, MD, Maxence Delomez, MD, Octave Equine, MD, Sylvie Tondeux, MD, Christophe Bauters, MD.Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: Prevalence, correlates and impact on prognosis (from the CORONOR study).Am Heart J.June 23 2014. 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1900423, encodeId=f48a1900423d1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Dec 07 12:10:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355875, encodeId=449113558e5b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402157, encodeId=2fcf140215e06, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562248, encodeId=ed3b15622480e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-12-07 jiangfeng5067

    #稳定性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1900423, encodeId=f48a1900423d1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Dec 07 12:10:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355875, encodeId=449113558e5b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402157, encodeId=2fcf140215e06, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562248, encodeId=ed3b15622480e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 zhaojie88

    #ART#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1900423, encodeId=f48a1900423d1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Dec 07 12:10:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355875, encodeId=449113558e5b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402157, encodeId=2fcf140215e06, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562248, encodeId=ed3b15622480e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 bioon4

    #双重抗血小板治疗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1900423, encodeId=f48a1900423d1, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Dec 07 12:10:00 CST 2014, time=2014-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355875, encodeId=449113558e5b3, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402157, encodeId=2fcf140215e06, content=<a href='/topic/show?id=26163e63362' target=_blank style='color:#2F92EE;'>#双重抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37633, encryptionId=26163e63362, topicName=双重抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6ka7cRR8xsokbAYjhg0mZeBm79vHeyXiaMibkYndHaibgmfg1JDA0AXlGaY8Og4IiaREUFYuBwekPoQ/132, createdBy=19852392148, createdName=bioon4, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562248, encodeId=ed3b15622480e, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Jun 28 00:10:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 爆笑小医

    #HEART#

    0

相关资讯

胡大一:优化稳定性冠心病和心衰治疗的新选择

胡大一教授          1、欧洲药监局批准伊伐布雷定心衰新适应证      2012年2月9日欧洲药品监管局（EMEA）正式批准伊伐布雷定的第三项临床适应证：合并收缩功能异常的慢性心力衰竭(心衰)治疗。该适应证的获批是基于SHIFT研究结果，即伊伐布雷定在β受体阻滞剂等传统药物治疗基础

NEJM：Dalcetrapib对近期有急性冠脉综合征的稳定性冠心病患者的疗效

　　背景  在观察性分析中，较高水平的高密度脂蛋白胆固醇（HDL-C）与冠心病事件的较低危险相关。然而，通过治疗升高的HDL-C水平是否降低心血管危险尚不确定。抑制胆固醇酯转运蛋白（CETP）可使HDL-C水平升高，因此有可能改善心血管转归。 　　方法  我们随机分配15871 例近期有过急性冠脉综合征的患者,除接受最佳可用循证医疗之外，还接受600 mg/d 的CETP 抑